Invokana (Canagliflozin) is a drug used for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson in the United States. It belongs to the class sodium-glucose cotransporter 2 (SGLT2) inhibitor. SGLT2 is an enzyme in the kidney tubule that causes glucose to be reabsorbed from urine. By inhibiting the action of SGLT2, Invokana helps the kidneys get rid of glucose from the bloodstream. The U.S. Food & Drug Administration (FDA) approved Invokana on March 29, 2013, for the treatment of type 2 diabetes.